 Research article
 Open Access
 Open Peer Review
 Published:
Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes
BMC Medical Research Methodology volume 19, Article number: 129 (2019)
The Correction to this article has been published in BMC Medical Research Methodology 2019 19:158
Abstract
Background
Multiple primary outcomes may be specified in randomised controlled trials (RCTs). When analysing multiple outcomes it’s important to control the family wise error rate (FWER). A popular approach to do this is to adjust the pvalues corresponding to each statistical test used to investigate the intervention effects by using the Bonferroni correction. It’s also important to consider the power of the trial to detect true intervention effects. In the context of multiple outcomes, depending on the clinical objective, the power can be defined as: ‘disjunctive power’, the probability of detecting at least one true intervention effect across all the outcomes or ‘marginal power’ the probability of finding a true intervention effect on a nominated outcome.
We provide practical recommendations on which method may be used to adjust for multiple comparisons in the sample size calculation and the analysis of RCTs with multiple primary outcomes. We also discuss the implications on the sample size for obtaining 90% disjunctive power and 90% marginal power.
Methods
We use simulation studies to investigate the disjunctive power, marginal power and FWER obtained after applying Bonferroni, Holm, Hochberg, Dubey/ArmitageParmar and StepdownminP adjustment methods. Different simulation scenarios were constructed by varying the number of outcomes, degree of correlation between the outcomes, intervention effect sizes and proportion of missing data.
Results
The Bonferroni and Holm methods provide the same disjunctive power. The Hochberg and Hommel methods provide power gains for the analysis, albeit small, in comparison to the Bonferroni method. The StepdownminP procedure performs well for complete data. However, it removes participants with missing values prior to the analysis resulting in a loss of power when there are missing data. The sample size requirement to achieve the desired disjunctive power may be smaller than that required to achieve the desired marginal power. The choice between whether to specify a disjunctive or marginal power should depend on the clincial objective.
Background
Multiple primary outcomes may be specified in a randomised controlled trial (RCT) when it is not possible to use a single outcome to fully characterise the effect of an intervention on a disease process [1,2,3]. The use of multiple primary outcomes (or ‘endpoints’) is becoming increasingly common in RCTs. For example, a third of neurology and psychiatry trials use multiple primary outcomes [4]. Data on two primary outcomes (abstinence and time to dropout from treatment) were collected in a trial evaluating the effectiveness of a behavioural intervention for substance abuse [5] and data on four primary outcomes were collected in a trial evaluating a multidisciplinary intervention in patients following a stroke [6]. Typically, these outcomes are correlated and often one or more of the outcomes has missing values.
Typically multiple statistical tests are performed to investigate the effectiveness of the intervention on each outcome. If two outcomes are analysed independently of each other at the nominal significance level of 0.05, then the probability of finding at least one false positive significant results increases to 0.098. This probability is known as the familywise error rate, ‘FWER’. One approach to control the FWER to its desired level is to adjust the pvalues corresponding to each statistical test used to investigate the intervention effects. Many adjustments have been proposed including the Bonferroni [7], Holm [8], Hochberg [9], Hommel [10] and Dubey/ArmitageParmar [11] methods. Once the pvalues have been adjusted, they can be compared to the nominal significance level. For example in the trial on substance abuse [5], two unadjusted pvalues: 0.010,0.002 were reported. If the Bonferroni method was used, the pvalues could have been adjusted to 0.020, 0.004 and compared to the significance level α of 0.05. Alternatively, the significance level could be adjusted (to 0.05/2 = 0.025 in this example) and compared to the unadjusted pvalues.
In clinical trials, it is also important to consider the power of the tests to detect an intervention effect. In the context of multiple outcomes, the power of the study can be defined in a number of ways depending on the clinical objective of the trial: i) ‘disjunctive power’, ii) ‘conjunctive power’ or iii) ‘marginal power’ [12].
The disjunctive power (or minimal power [13]) is the probability of finding at least one true intervention effect across all of the outcomes [12, 14]. The conjunctive power (or maximal power [13]) is the probability of finding a true intervention effect on all outcomes [14]. It may be noted that the disjunctive and conjunctive power have previously been referred to as ‘multiple’ and ‘complete’ power respectively [13]. The marginal (or individual) power is the probability of finding a true intervention effect on a particular outcome and is calculated separately for each outcome. When the clinical objective is to detect an intervention effect for at least one of the outcomes the disjunctive power and marginal power are recommended whereas the conjunctive power is recommended when the clinical objective is to detect an intervention effect on all the outcomes [12, 14]. In this paper, we are focusing on the former clinical objective and therefore we focus on disjunctive and marginal power.
The power requirements of a trial should match the clinical objective which needs to be prespecified when designing the study and the sample size calculation should be performed accordingly. In current practice, the sample size calculations for trials often focus on the marginal power for each outcome. An approach that has been recommended and is often used in trials is to calculate the sample size separately for each of the primary outcomes by applying a Bonferroni correction to adjust the significance level [15]. The largest value of the sample size is then considered as the final sample size for the trial [16].
Missing outcome data are common in RCTs [17] which will inevitably reduce the power and efficiency of the study [18] which may result in failure to detect true intervention effects as statistically significant.
When using multiple primary outcomes, there is limited guidance as to which method(s) should be used to take account of multiplicity in the sample size calculation and during the statistical analysis.
Some studies have compared a selection of methods which adjust pvalues to account for multiplicity to handle multiple outcomes in trials. Sankoh, Huque and Dubey [11] compare a selection of adjustment methods for statistical analysis in terms of FWER but they do not evaluate the methods with respect to the power obtained. Blakesley et al. discuss both FWER and power requirements for selected methods for a large number of outcomes with varying degrees of correlation [19]. Lafaye de Micheaux provide formulae to calculate the power and sample size for multiple outcomes [20] which require several assumptions to be made about the outcomes, including normality and whether the covariance matrix between the outcomes is known or not. They discuss global testing procedures, including the Hotelling T^{2} method. None of these studies have investigated the adjustment methods in the presence of missing data.
There is limited literature discussing the sample size requirements for clinical trials with multiple primary outcomes where the clinical objective is to detect an intervention effect for at least one of the outcomes. Dmitrienko, Tamhane and Bretz [14] and Senn and Bretz [13] provide some discussion regarding the sample size in the context of multiple outcomes. However, neither discuss sample size in the context of which adjustment method should be used and they do not provide a comparative table depending on the type of desired power to show implications on the required sample sizes.
In this paper, we compare easy to use methods to adjust pvalues in terms of FWER and power, when investigating two, three and four outcomes in presence of complete outcome data and outcome data with missing values. We also consider a range of correlations between the outcomes. We consider both marginal and disjunctive power. Based on our findings, we provide practical recommendations on the adjustment methods which could be used for the sample size calculation and analysis of RCTs with multiple primary outcome. We also present tables showing the implications of using the marginal and disjunctive power on the required sample size for a trial under different scenarios.
Methods
We assume that we have a twoarm trial in which there are M primary outcomes. We are interested in testing the null hypotheses H_{j} (j = 1, … , M) that there is no intervention effect on the nominated outcomes. The test statistics t_{j} are used to test the null hypotheses H_{j}. Further suppose that there is an overall null hypothesis \( H(M)={\bigcap}_{j=1}^M{H}_j. \) Under this overall hypothesis, the joint test statistic (t_{1}, … , t_{M}) has a Mvariate distribution. We denote p_{j} as the marginal, unadjusted pvalues obtained from the appropriate statistical test associated with analysing each outcome separately in a univariate framework. For example, when analysing continuous outcomes, an unpaired Student’s ttest may be used or when analysing binary outcomes a Chisquared test may be used to investigate the intervention. To control the FWER a correction method is then applied to the unadjusted pvalues (p_{j}). We compare the following commonly used adjustment methods in this paper: Šidák, Bonferroni, Holm, Hochberg and Hommel. In addition, we consider the Dubey/ArmitageParmar (D/AP) adjustment and Stepdown minP resampling procedure which take account of the pairwise correlation between the outcomes.
The method proposed by Šidák is defined as \( {p}_j^{\overset{\check{} }{\mathrm{S}}\mathrm{i}}=1{\left(1{p}_j\right)}^M \). Equivalently, the significance level could be adjusted to \( {\alpha}^{\overset{\check{} }{\mathrm{S}}\mathrm{i}}=1{\left(1\alpha \right)}^{1/M} \), where α is the unadjusted significance level. Under the assumption that the outcomes are independent, the adjustment can be derived as
The Bonferroni method is the most common approach to account for multiplicity due to its simplicity. In this method, the unadjusted pvalues p_{j} are multiplied by the number of primary outcome. The Dubey/ArmitageParmar (D/AP) is an adhoc method based on the Šidák method, which takes into account the correlation between the outcomes [11]. The adjusted pvalue is \( {p}_j^{adj}=1{\left(1{p}_j\right)}^{g(j)} \) where g(j) = M^{1 − mean ρ(j)} and mean ρ(j) is the mean correlation between the j^{th} outcome and the remaining M − 1 outcomes. When using this method in the analysis of multiple outcomes, the mean correlation may be estimated from the data. There has been little theoretical work to assess the performance of this approach [11].One of the nice properties of the D/AP procedure, which may have contributed to its development, is that when the average of the correlation coefficients is zero, the D/AP adjustment is according to the Bonferroni test, and when the average correlation coefficient is one, the D/AP adjusted and the unadjusted pvalues are the same. The Holm method [8] involves a stepdown method, whereby the unadjusted pvalues are ordered from smallest p_{(1)} to largest p_{(M)} and each unadjusted pvalue is adjusted as \( {p}_{(k)}^{Holm}=\left(Mk+1\right)\ {p}_{(k)} \), where k = 1, … M is the rank of the corresponding pvalue. Then starting with the most significant pvalue (smallest pvalue), each adjusted pvalue is compared to the nominal significance level, until a pvalue greater than the significance level is observed after which the method stops [21]. The Hochberg stepup method [9] is similar to the Holm stepdown method but works in the other direction. For this method, the unadjusted pvalues are ranked from largest p_{(1)} to smallest p_{(M)} and adjusted as \( {p}_{(k)}^{Hoch}=\left(Mk+1\right)\ {p}_{(k)} \). Starting with the least significant pvalue (largest pvalue), each adjusted pvalue is compared to the prespecified significance level, until a pvalue lower than the significance level is observed after which the method stops [21]. Contrary to the Šidák based approaches, this is a semiparametric method meaning the FWER is only controlled when the joint distribution of the hypotheses test statistics is known, most commonly multivariate normal [22]. The Hommel method [10] is another datadriven stepwise method. For this method, the unadjusted pvalues are ranked from largest p_{(M)} to smallest p_{(1)}. Then let l be the largest integer for which \( {p}_{\left(Ml+j\right)}>\frac{j\alpha}{l} \) or all j = 1, … l. If no such j exists then all outcomes can be deemed statistically significant; otherwise, all outcomes with \( {p}_i\le \frac{\alpha }{j} \) may be deemed statistically significant, where j = 1, … , M; i = 1, … , M. To control the FWER, the Hommel method requires that the joint distribution of the overall hypothesis test statistic is known.
Another stepdown method to adjust pvalues is the ‘Stepdown minP’ procedure [23, 24]. Unlike the previous methods, it does not make any assumptions regarding the distribution of the joint test statistic. Instead it attempts to approximate the true joint distribution by using a resampling approach. This method takes into account the correlation structure between the outcomes and therefore may yield more powerful tests compared to the other adjustment methods [25]. The Stepdown minP adjusted pvalues are calculated as follows: 1) calculate the observed test statistics using the observed data set; 2) resample the data with replacement within each intervention group to obtain bootstrap resamples, compute the resampled test statistics for each resampled data set and construct the reference distribution using the centred and/or scaled resampled test statistics; 3) calculate the critical value of a level α test based on the upper α percentile of the reference distribution, or obtain the raw pvalues by computing the proportion of bootstrapped test statistics that are as extreme or more extreme than the observed test statistic [26]. That is, the Stepdown minP adjusted pvalue for the j^{th} outcome is defined as [24, 26] \( {p}_j^{minP}={\max}_{k=1,\dots, j}\left\{\kern0.5em \Pr \left(\left(\ {\min}_{l=k,\dots, M}\kern.45em {p}_l\le {p}_k\kern0.5em \right\kern0.5em H(M)\right)\right\}, \) where p_{k} is the unadjusted pvalue for the k^{th} outcome, p_{l} is the unadjusted pvalue for the l^{th} outcome (l = k, … , M), and H(M) is the overall null hypothesis.
Although, the resampling based methods have previously been recommended for clinical trials with multiple outcomes they are not widely used in practice [25]. The Stepdown minP has been shown to perform well when compared to other resampling procedures [26] and was therefore investigated in this paper.
We perform a simulation study to evaluate the validity of these methods to account for potentially correlated multiple primary outcomes in the analysis and sample size of RCTs. We focus on two, three and four outcomes as a review of trials with multiple primary outcomes in the psychiatry and neurology field found that the majority of the trials had considered two primary outcomes [4]. Additionally, it has been recommended that a trial should have no more than four primary outcomes [27]. We estimate the family wise error rate (FWER), the disjunctive power to detect at least one intervention effect and the marginal power to detect an intervention effect on a nominated outcome in a variety of scenarios.
Simulation study
We used the following model to simulate values for two continuous outcomes Y_{i} = (Y_{i, 1}, Y_{i, 2}),
where x_{i} indicates whether the participant i received intervention or control, β_{1} = ( β_{11}, β_{12} )^{T} is vector of the intervention effects for each outcome, ϵ_{i} are errors which are realisations of a multivariate normal distribution \( {\boldsymbol{\epsilon}}_{\boldsymbol{i}}={\left({\epsilon}_{i,1},{\epsilon}_{i,2}\ \right)}^T\sim N\left(\left(\genfrac{}{}{0pt}{}{0}{0}\right),\left(\begin{array}{cc}1& \rho \\ {}\rho & 1\end{array}\right)\ \right), \) and ρ ϵ {0.0, 0.2, 0.4, 0.6, 0.8}. The model was also extended to simulate three and four continuous outcomes. When simulating three and four outcomes we specified compound symmetry, meaning that the correlation between any pair of outcomes is the same. We explored both uniform intervention effect sizes and varying effect sizes across outcomes. For the uniform intervention effect sizes, we specified an effect size of 0.35 for all outcomes, that is β_{1} = (0.35, 0.35)^{T}, β_{1} = (0.35, 0.35, 0.35)^{T} or β_{1} = (0.35, 0.35, 0.35, 0.35)^{T} for two, three and four outcomes scenarios respectively. This represents a medium effect size, which reflects the anticipated effect size in many RCTs [28]. For the varying intervention effect sizes, we specified that β_{1} = (0.2, 0.4)^{T}, β_{1} = (0.2, 0.3, 0.4)^{T} or β_{1} = (0.1, 0.2, 0.3, 0.4)^{T} for two, three and four outcomes scenarios respectively. We also explored the effect of skewed data by transforming the outcome data with uniform intervention effect sizes to have a gamma distribution with shape parameter = 2 and a scale parameter = 2. The gamma distribution is often used to model healthcare costs in clinical trials [29, 30] and may also be appropriate for skewed clinical outcomes.
We set the sample size to 260 participants, with an equal number of participants assigned to each arm. This provides 80% marginal power to detect a clinically important effect size of 0.35 for each outcome, using an unpaired Student’s ttest and the significance level is unadjusted at 0.05. We introduced missing data under the assumption that the data were missing completely at random (MCAR). When simulating two outcomes, 15 and 25% of the observations in outcome 1 and 2 are missing respectively, and on average approximately 4% of the observations would be missing for both outcomes. When simulating three outcomes, 15% of the observations are missing in one outcome and 25% of the observations are missing in the other two outcomes. When simulating four outcomes, 15% of the observations are missing in two outcomes and 25% of the observations are missing in the other two outcomes. This proportion of missingness in outcomes is often observed in RCTs [31,32,33,34].
We estimated the FWER and disjunctive power by specifying no intervention effect (β_{1j} = 0) and an intervention effect (β_{1j} ≠ 0), respectively, and calculating the proportion of times an intervention effect was observed on at least one of the outcomes. The marginal power was similarly estimated but we calculated the proportion of times an intervention effect was observed on the nominated outcome. For each scenario we ran 10,000 simulations. The simulations were run using R version 3.4.2. The Stepdown minP procedure was implemented using the NPC package.
We calculated the sample size based on disjunctive power using the R package “mpe” [35] and we calculated the sample size based on the marginal power using the R package “samplesize” [36]. The statistical methodology used for the sample size calculation in these packages is described in the Additional file 1.
Results
The Bonferroni and Holm methods lead to the same FWER and disjunctive power when analysing multiple primary outcomes. This is because both methods adjust the smallest pvalue in the same way. Similarly, the Hochberg and Hommel methods lead to same FWER and disjunctive power when two primary outcomes are analysed and differences between these methods arise when analysing three or more outcomes.
Family wise error rate, FWER
The FWER obtained when evaluating two, three and four outcomes are displayed in Figs. 1, 2 and 3 respectively. Following on from the explanation above, the Holm and Hommel methods are not displayed in Fig. 1 and the Holm method is not displayed in Fig. 2 or 3. The results for the varying intervention effect sizes and skewed data are presented in the Additional file 1.
When there is correlation between the outcomes (ρ ≥ 0.2), the D/AP method does not control the FWER. All other adjustment methods control the FWER in all scenarios. The Stepdown minP performs well in terms of FWER. Unlike the other methods, it maintains the error rate at 0.05 even when the strength of the correlation between the outcomes increases. Differences between the Bonferroni, Hochberg and Hommel methods arise when there is moderate correlation between outcomes (ρ ≥ 0.4). The Hommel provides the FWER which is closest to 0.05, whilst being controlled, followed by Hochberg and then Bonferroni. Very similar results were observed when the outcomes followed a skewed distribution, consequently these results are presented in the Additional file 1.
Disjunctive power
Figures 1, 2 and 3 show that the disjunctive power decreases as the correlation between the outcomes increases for all approaches. We do not consider the power obtained when using the D/AP approach due to its poor performance in controlling the FWER. When there is no missing data, the Stepdown minP and Hommel approaches provide the highest disjunctive power. For weak to moderate correlation (ρ = 0.2 to 0.6) the Hommel method has slightly more disjunctive power, but the Stepdown minP performs better when there is strong correlation (ρ = 0.8). The Stepdown minP procedure gives the lowest power in the presence of missing data. This could be attributed to the fact that it uses listwise deletion removing participants with at least one missing value prior to the analysis thus resulting in a loss of power when there is missing data. As expected the Bonferroni method gives slightly lower power compared to the other methods for complete data but considerably out performs the Stepdown minP method when there is missing data. Very similar results were observed when the outcomes followed a skewed distribution.
When the intervention effect sizes varied, the differences observed between the methods were less pronounced. When using four outcomes with varying effect sizes, very similar disjunctive power were observed to that of constant effect sizes. When using the Hommel adjustment, higher disjunctive power was observed compared to the Holm and Bonferroni methods albeit by a very minimal amount.
Marginal power
The marginal power obtained for each outcome when using the different adjustment methods are shown in Table 1. In terms of marginal power, the Hommel adjustment was the most powerful method, followed closely by the Hochberg method. When two independent outcomes were analysed, a power of 76.8% was observed after applying a Hommel correction. The power decreased to 76.8 and 75.2% when three and four outcomes were analysed, respectively, after applying a Hommel correction. As expected the Bonferroni method was the most conservative method, providing the least power. However, contrary to popular belief, the Bonferroni method maintains similar levels of power as the strength of correlation increases.
When analysing two outcomes the percentage of simulations in which an intervention effect was observed on neither outcome, one outcome or both outcomes are shown in Table 2. When using the Holm method, a statistically significant intervention effect was observed on both outcomes in 48–58% of the simulations. This reduced to 36–48% of the simulations when using the Bonferroni method. As expected, when using the Hochberg adjustment the same results were observed as when using the Hommel adjustment. Compared to Holm, slightly higher percentages of simulations with two statistically significant intervention effects are observed when using Hochberg and Hommel.
Sample size calculation
We recommend the Bonferroni adjustment to be used for the sample size calculation when designing trials with multiple correlated outcomes since it can be applied easily by adjusting the significance level and it maintains the FWER to an acceptable level up to a correlation of 0.6 between outcomes. As the Hochberg and Hommel methods are datadriven, it is not clear how these more powerful approaches can be incorporated into the sample size calculation unless prior data are available. Determination of the required sample size using these methods may require simulationbased approach.
In Table 3, we present the required sample sizes to obtain 90% disjunctive power for trials with two outcomes for varying degrees of correlations between the outcomes (ρ = {0.2, 0.4, 0.6, 0.8}). For these calculations, we specified that there is equal allocation of participants between the intervention arms. To calculate the sample size a priori information on the degree of correlation between the outcomes is required. More details regarding the sample size calculation are provided in [13]. For comparison, we also present the sample size required to obtain 90% marginal power for each outcome. For all calculations, we have used the Bonferroni method to account for multiple comparisons. We provide the sample sizes required to analyse two, three and four outcomes in Tables 3, 4 and 5, respectively. In Table 5, the top line provides an example sample size calculation for four outcomes where there is a small standardised effect size for all four outcomes (Δ = 0.2). When there is weak pairwise correlation between all four outcomes (ρ = 0.2), 325 participants would be required into each arm to obtain 90% disjunctive power. As the pairwise correlation increases to ρ = 0.8 the required sample size increases to 529. The sample size required to obtain 90% marginal for each outcome in this scenario is 716 participants per trial arm. The number of participants required to obtain 90% marginal power is greater than the number of participants required to obtain 90% disjunctive power. Thus the required sample size varies considerably depending on whether marginal or disjunctive power is used. The smallest of the sample sizes required to obtain the desired marginal power is the required sample size to achieve 90% disjunctive power if the outcomes are perfectly correlated (ρ = 1) [37].
Discussion
When using multiple primary outcomes in RCTs it is important to control the FWER for confirmatory phase III trials. One approach to do this is to adjust the pvalues produced by each statistical test for each outcome. Additionally, some of the outcomes are likely to have missing values, consequently this needs to be considered when choosing an appropriate method to adjust the pvalues.
Statistical analysis
We found that all methods investigated, except the D/AP, controlled the FWER. This agrees with the results previously reported in [19]. The Stepdown minP performed best in terms of FWER, but the R package used to implement the method uses listwise deletion removing participants with at least one missing value before the analysis resulting in a loss of power. The validity of this approach depends on how the method is implemented and the extent of the missing data.
We recommend that the Hommel method is used to control FWER when the distributional assumptions are met, as it provides slightly more disjunctive power than the Bonferroni and Holm methods. The distributional assumption associated with the Hommel method is not restrictive and is met in many multiplicity problems arising in clinical trials [22]. Even when the data followed a skewed distribution, the Hommel method performed well, showing it may be used to analyse a variety of outcomes, including those with a skewed distribution.
Given the availability of the software packages to implement the more powerful approaches, there is little reason to use the less powerful methods, such as Holm method. For example, the Hommel method can easily be implemented in R or SAS. Even though it is not currently available in Stata or SPSS, the pvalues can be copied across and adjusted in R. However, if the assumptions cannot be met, the simpler Holm method could be used.
When the intervention effect size varied across the outcomes, we found that the differences in disjunctive power between the methods were less pronounced. It appeared that the outcome with the largest effect size ‘dominated’ the disjunctive power. When the sample size is based on the disjunctive power, the outcomes with the largest effect size would have high marginal power, whereas the outcome with the smallest effect size would have low marginal power – much below the overall desired level of power. It follows that when investigators are looking for an intervention effect for at least one outcome, it is unlikely that they will see an intervention effect on the outcomes with the smaller effect sizes without seeing an intervention effect on the outcomes with the largest effect size. Consequently, in this scenario, it may be advisable to pick the outcome(s) with the largest effect size as the primary outcome(s) and treat the other outcomes as secondary outcomes, however, this decision will need to account for the relative clinical importance of the outcomes. Alternatively, when the intervention effect size varies across the outcomes, investigators may wish to consider ‘alpha spending’ in which the total alpha (usually 0.05) is distributed or ‘spent’ across the M analyses.
We appreciate that in practice the choice of the adjustment method may also depend on other factors, such as the availability of simultaneous confidence intervals and unbiased estimates. It is standard practice to report the 95% confidence intervals alongside point estimates and pvalues. When using multiple primary outcomes, it may be necessary to adjust the confidence interval so that it corresponds to the pvalues adjusted for multiplicity. The confidence interval may be easily adjusted when using Bonferroni or Holm adjustments, using the R function “AdjustCIs” in the package “Mediana” [38]. However, it is not straightforward to adjust the confidence interval when using the Hochberg and Hommel. Consequently, the confidence intervals reported may not align with the pvalues when these adjustments are used. As stated in the European Medical Agency (EMA) guidelines, in this instance, the conclusions should be based on the pvalues and not the confidence intervals [3]. If confidence intervals that correspond to the chosen multiplicity adjustment are not available or are difficult to derive, then the EMA guidelines advise that simple but conservative confidence intervals are used, such as those based on Bonferroni correction [3].
The statistical analysis plan of a trial should clearly describe how the outcomes will be tested including which adjustment method, if any, will be used [39].
Our review of trials with multiple outcomes showed that majority of the trials analysed the outcomes separately without any adjustments for multiple comparisons [4]. Where adjustment methods were used, only the most basic methods were used, possibly due to their ease of implementation. The Bonferroni method was the most commonly used method, although the Holm and Hochberg methods were also used. As a consequence, we focused on relatively simple techniques in this paper. However, more advanced approaches, such as graphical methods to control the FWER are available and described in Bretz et al. [40] and Bretz et al. [41] .
It is not necessary to control the FWER for all types of trial designs, for example, for trial designs with coprimary outcomes where all outcomes have to be declared statistically significant for the intervention to be deemed successful. The FDA guidelines state that in this scenario no adjustment needs to be made to control the FWER [39] and the ‘conjunctive’ power is used. We have not evaluated the conjunctive power as it is not relevant to the scenarios considered in this paper. The conjunctive power may be substantially reduced compared to the marginal power for each outcome [39] and is never larger than the marginal power [13]. The conjunctive power behaves in reverse to the disjunctive power in that as the correlation between the outcomes increases, the conjunctive power increases.
Additionally, multiplicity adjustments may not be necessary for early phase drug trials. However, it is generally accepted that adjustments to control the FWER are required in confirmatory studies, that is when the goal of the trial is the definitive proof of a predefined key hypothesis for the final decision making [42].
Sample size
When designing a clinical trial, it is important to calculate the sample size needed to detect a clinically important intervention effect. Usually the number of participants that can be recruited in a trial is restricted because of ethical, cost and time implications. The sample size calculation for a trial is usually based on an appropriate statistical method which will be used for the primary analysis depending on the study design and objectives. The sample size can vary greatly depending on if the marginal power or overall disjunctive power is used highlighting the importance of calculating the sample size based on the trial objective. To account for multiplicity in the sample size calculation, we recommend that the Bonferroni adjustment is used. The Bonferroni adjustment can be applied easily within the sample size calculation using an analytical formula [39] and our simulation study showed that it maintains the FWER to an acceptable level for low to moderate correlation between the outcomes. Additionally, there is not much loss in power when using the Bonferroni adjustment, compared to the other methods, in the presence of missing data. In contrast, the other methods investigated in this paper are data driven and therefore it is not clear how these can be incorporated without prior data.
One approach that has previously been used to calculate the sample size for multiple primary outcomes, was to calculate the sample size based on the individual marginal powers for each outcome and to choose the maximum sample size for the trial [43]. This approach guarantees adequate marginal power for each individual test. However, this approach will overestimate the number of participants required if the investigators are interested in disjunctive power. Moreover, it may be problematic to achieve that sample size in trials where recruitment is a problem and may result in trials being closed down prematurely. Finally, the sample size should be inflated to account for the expected amount of missing data.
Study extensions and limitations
In this paper, we only explored continuous outcomes. However, in RCTs binary outcomes or a combination of continuous and binary outcomes may be used. For two binary outcomes, the maximum possible pairwise correlation between the outcomes will be less than one in absolute magnitude [44] and therefore we would expect similar results but with less pronounced differences between methods for the strong correlations.
Additionally, we only explored global effects, that is either no interventions effect on any of the outcomes (β_{1j} = 0 ) or an intervention effect on all the outcomes (β_{1j} ≠ 0). Global effects are most realistic when the strength of the correlation between the outcomes is moderate to strong. However, in practice a mixture of no effects and some intervention effects may be observed, especially when the strength of the correlation between the outcomes is weak.
Conclusions
To ensure that the FWER is controlled when analysing multiple primary outcomes in confirmatory randomised controlled trials, we recommend that the Hommel method is used in the analysis for optimal power, when the distributional assumptions are met. When designing the trial, the sample size should be calculated according to the trial objective. When specifying multiple primary outcomes, if considered appropriate, the disjunctive power could be used, which has smaller sample size requirements compared to that when using the individual marginal powers. The Bonferroni adjustment can be used in the sample size calculation to account for multiplicity.
Availability of data and materials
The datasets analysed during the current study are available from the corresponding author on reasonable request.
Change history
22 July 2019
In the original publication of this article [1], “=1 − = 1 − ≈ s” was mistakenly added after the sentence “ In this method, the unadjusted pvalues pj are multiplied by the number of primary outcome” in the Methods section, and should be deleted.
Abbreviations
 CI:

Confidence interval
 D/AP:

Dubey/ArmitageParmar
 FWER:

Familywise error rate
 MCAR:

Missing completely at random
 SE:

Standard error
References
 1.
TeixeiraPinto A, Siddique J, Gibbons R, Normand SL. Statistical approaches to modeling multiple outcomes in psychiatric studies. Psychiatr Ann. 2009;39(7):729.
 2.
De Los Reyes A, Kundey SMA, Wang M. The end of the primary outcome measure: a research agenda for constructing its replacement. Clin Psychol Rev. 2011;31(5):829–38.
 3.
European Medical Agency: Guideline on multiplicity issues in clinical trials.2017.
 4.
Vickerstaff V, Ambler G, King M, Nazareth I, Omar RZ. Are multiple primary outcomes analysed appropriately in randomised controlled trials? A review. Contemp Clin Trials. 2015;45:8–12.
 5.
Campbell AN, Nunes EV, Matthews AG, Stitzer M, Miele GM, Polsky D, Turrigiano E, Walters S, McClure EA, Kyle TL. Internetdelivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatr. 2014;171(6):683–90.
 6.
Middleton S, McElduff P, Ward J, Grimshaw JM, Dale S, D'Este C, Drury P, Griffiths R, Cheung NW, Quinn C. Implementation of evidencebased treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet. 2011;378(9804):1699–706.
 7.
Gelman A, Hill J, Yajima M. Why we (usually) don't have to worry about multiple comparisons. J Res Educ Effectiveness. 2012;5(2):189–211.
 8.
Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6(2):65–70.
 9.
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800–2.
 10.
Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika. 1988;75(2):383–6.
 11.
Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med. 1997;16(22):2529–42.
 12.
Bretz F, Hothorn T, Westfall P. Multiple comparisons using R. Boca Raton: CRC Press; 2010.
 13.
Senn S, Bretz F. Power and sample size when multiple endpoints are considered. Pharm Stat. 2007;6(3):161–70.
 14.
Dmitrienko A, Tamhane AC, Bretz F. Multiple testing problems in pharmaceutical statistics. Boca Raton: CRC Press; 2009.
 15.
Chow SC, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research. Boca Raton: Chapman and Hall/CRC; 2017.
 16.
Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, Beute GN, van Vugt JP, Lenders MW, Contarino MF. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2012;12(1):37–44.
 17.
Bell ML, Fiero M, Horton NJ, Hsu CH. Handling missing data in RCTs; a review of the top medical journals. BMC Med Res Methodol. 2014;14(1):118.
 18.
Kang H. The prevention and handling of the missing data. Korean J Anesthesiol. 2013;64(5):402.
 19.
Blakesley RE, Mazumdar S, Dew MA, Houck PR, Tang G, Reynolds CF III, Butters MA. Comparisons of methods for multiple hypothesis testing in neuropsychological research. Neuropsychology. 2009;23(2):255.
 20.
Lafaye de Micheaux P, Liquet B, Marque S, Riou J. Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints. J Biopharm Stat. 2014;24(2):378–97.
 21.
Wright SP. Adjusted pvalues for simultaneous inference. Biometrics. 1992;48(4):1005–13.
 22.
Dmitrienko A, D'Agostino R. Traditional multiplicity adjustment methods in clinical trials. Stat Med. 2013;32(29):5172–218.
 23.
Westfall PH, Young SS. Resamplingbased multiple testing: examples and methods for pvalue adjustment, vol. 279. New York: Wiley; 1993.
 24.
Ge Y, Dudoit S, Speed TP. Resamplingbased multiple testing for microarray data analysis. Test. 2003;12(1):1–77.
 25.
Reitmeir P, Wassmer G. Resamplingbased methods for the analysis of multiple endpoints in clinical trials. Stat Med. 1999;18(24):3453–62.
 26.
Li D, Dye TD. Power and stability properties of resamplingbased multiple testing procedures with applications to gene oncology studies. Comput Math Methods Med. 2013;2013:610297.
 27.
Capizzi T, Zhang J. Testing the hypothesis that matters for multiple primary endpoints. Drug Inf J. 1996;30(4):949–56.
 28.
Rothwell JC, Julious SA, Cooper CL. A study of target effect sizes in randomised controlled trials published in the health technology assessment journal. Trials. 2018;19(1):544.
 29.
Thompson SG, Nixon RM. How sensitive are costeffectiveness analyses to choice of parametric distributions? Med Decis Mak. 2005;25(4):416–23.
 30.
Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and betweenCentre differences into costeffectiveness evaluations. Health Econ. 2005;14(12):1217–29.
 31.
Beeken R, Leurent B, Vickerstaff V, Wilson R, Croker H, Morris S, Omar R, Nazareth I, Wardle J. A brief intervention for weight control based on habitformation theory delivered through primary care: results from a randomised controlled trial. Int J Obes. 2017;41(2):246–54.
 32.
Osborn DP, Hardoon S, Omar RZ, Holt RI, King M, Larsen J, Marston L, Morris RW, Nazareth I, Walters K. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry. 2015;72(2):143–51.
 33.
Hassiotis A, Poppe M, Strydom A, Vickerstaff V, Hall IS, Crabtree J, Omar RZ, King M, Hunter R, Biswas A. Clinical outcomes of staff training in positive behaviour support to reduce challenging behaviour in adults with intellectual disability: cluster randomised controlled trial. Br J Psychiatry. 2018;212(3):161–8.
 34.
Killaspy H, Marston L, Green N, Harrison I, Lean M, Cook S, Mundy T, Craig T, Holloway F, Leavey G. Clinical effectiveness of a staff training intervention in mental health inpatient rehabilitation units designed to increase patients’ engagement in activities (the rehabilitation effectiveness for activities for life [REAL] study): singleblind, clusterrandomised controlled trial. Lancet Psychiatry. 2015;2(1):38–48.
 35.
Kohl M, Kolampally S. mpe: multiple primary endpoints; 2017.
 36.
Scherer R. Samplesize: sample size calculation for various ttests and WilcoxonTest; 2016.
 37.
Sozu T, Kanou T, Hamada C, Yoshimura I. Power and sample size calculations in clinical trials with multiple primary variables. Jpn J Biometrics. 2006;27(2):83–96.
 38.
Paux G, Dmitrienko A. Package ‘Mediana’: Clinical Trial Simulations. 1.0.7 ed; 2018.
 39.
Food, Administration D: Multiple endpoints in clinical trials guidance for industry. Food and Drug Administration Draft Guidance. Multiple endpoints in clincial trials guidnace for industry. Silver Springer. 2017.
 40.
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom J. 2011;53(6):894–913.
 41.
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med. 2009;28(4):586–604.
 42.
Bender R, Lange S. Adjusting for multiple testing—when and how. J Clin Epidemiol. 2001;54(4):343–9.
 43.
Allen RP, Chen C, GarciaBorreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370(7):621–31.
 44.
Warner RM. Applied statistics: from bivariate through multivariate techniques: sage; 2008.
Acknowledgements
Not applicable.
Funding
Victoria Vickerstaff is supported by Marie Curie Core funding grant [MCCCFCO16U], National Institute Health Research School of Primary Care Research Seedcorn funding grant and UCLH Biomedical Research Centre. Rumana Omar and Gareth Ambler’s research work was undertaken at University College London Hospitals /University College London who received a proportion of funding from the United Kingdom Department of Health’s National Institute for Health Research Biomedical Research Centres (NIHR BRC) funding scheme.
Author information
Affiliations
Contributions
VV, RO and GA conceived the concept of this study. VV carried out the simulations and drafted the manuscript. RO and GA critically reviewed and made substantial contributions to the manuscript. All authors approved the final manuscript.
Corresponding author
Correspondence to Victoria Vickerstaff.
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original version of this article was revised: =1 − = 1 − ≈ s’ was mistakenly added after the sentence ‘In this method, the unadjusted pvalues pj are multiplied by the number of primary outcome’ in the Methods section, and should be deleted.
A correction to this article is available online at https://doi.org/10.1186/s1287401908078.
Additional file
Additional file 1
Sample size calculation methodology. Varying the effect size across outcomes. Skewed data. (DOCX 1675 kb)
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Vickerstaff, V., Omar, R. & Ambler, G. Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes. BMC Med Res Methodol 19, 129 (2019) doi:10.1186/s1287401907544
Received
Accepted
Published
DOI
Keywords
 Multiple comparison methods
 Multiple outcome
 Sample size
 Statistical analysis
 Randomised controlled trials